ESRX - Express Scripts Holding Company

YHD - YHD Delayed Price. Currency in USD
At close: 6:07PM EDT
Stock chart is not supported by your current browser
Previous CloseN/A
YTD ReturnN/A
Expense Ratio (net)N/A
CategoryN/A
Last Cap GainN/A
Morningstar RatingN/A
Morningstar Risk RatingN/A
Sustainability RatingN/A
Net AssetsN/A
Beta (5Y Monthly)N/A
YieldN/A
5y Average ReturnN/A
Holdings TurnoverN/A
Last DividendN/A
Average for CategoryN/A
Inception DateN/A
  • Moody's

    Diplomat Pharmacy, Inc. -- Moody's reviews Diplomat Pharmacy for upgrade

    Moody's Investors Service ("Moody's") placed the ratings of Diplomat Pharmacy, Inc. ("Diplomat") under review for upgrade. Moody's changed the outlook to rating under review from developing. OptumRx is part of UnitedHealth Group Incorporated, which has senior unsecured debt rated A3 with a stable outlook.

  • Moody's

    Express Scripts Holding Company -- Moody's withdraws ratings on Express Scripts and Medco

    Express Scripts is a subsidiary of Cigna Corporation ("Cigna"). The majority of the debt of Express Scripts and Medco has been exchanged into direct obligations of Cigna through a recently completed exchange offer.

  • Moody's

    Diplomat Pharmacy, Inc. -- Moody's downgrades Diplomat Pharmacy to Caa1; developing outlook

    Moody's Investors Service ("Moody's") downgraded the ratings of Diplomat Pharmacy, Inc. ("Diplomat") including the Corporate Family Rating to Caa1 from B3, the Probability of Default Rating to Caa1-PD from B3-PD, the senior secured rating to Caa1 from B3 and the Speculative Grade Liquidity Rating to SGL-4 from SGL-3. The downgrade of the Corporate Family Rating to Caa1 from B3 reflects the recent decision by a large payer to begin excluding Diplomat from its specialty pharmacy network later this month, raising concerns about Diplomat's competitive position.

  • Moody's

    Express Scripts Holding Company -- Moody's comments on exchange offer for Express Scripts debt

    Moody's Investors Service commented that the recent exchange offer from Cigna Corporation to exchange debt of Express Scripts Holding Company ("Express Scripts") and Medco Health Solutions, Inc. ("Medco") for new obligations of Cigna Corporation has no immediate impact on the ratings of Express Scripts or Medco. Express Scripts and Medco are each rated Baa2 with a stable outlook.

  • Moody's

    Connecticut General Life Insurance Company -- Moody's announces completion of a periodic review of ratings of Cigna Corporation

    Moody's Investors Service ("Moody's") has completed a periodic review of the ratings of Cigna Corporation and other ratings that are associated with the same analytical unit. The review was conducted through a portfolio review in which Moody's reassessed the appropriateness of the ratings in the context of the relevant principal methodology(ies), recent developments, and a comparison of the financial and operating profile to similarly rated peers. This publication does not announce a credit rating action and is not an indication of whether or not a credit rating action is likely in the near future.

  • Moody's

    Diplomat Pharmacy, Inc. -- Moody's downgrades Diplomat Pharmacy to B3; outlook developing

    Moody's Investors Service ("Moody's") downgraded the ratings of Diplomat Pharmacy, Inc. ("Diplomat") including the Corporate Family Rating to B3 from B2, the Probability of Default Rating to B3-PD from B2-PD, and the senior secured rating to B3 from B2. At the same time, Moody's affirmed the SGL-3 Speculative Grade Liquidity Rating.

  • Moody's

    Express Scripts Holding Company -- Moody's announces completion of a periodic review of ratings of Express Scripts Holding Company

    Moody's Investors Service ("Moody's") has completed a periodic review of the ratings of Express Scripts Holding Company and other ratings that are associated with the same analytical unit. The review was conducted through a portfolio review in which Moody's reassessed the appropriateness of the ratings in the context of the relevant principal methodology(ies), recent developments, and a comparison of the financial and operating profile to similarly rated peers. This publication does not announce a credit rating action and is not an indication of whether or not a credit rating action is likely in the near future.

  • PR Newswire

    Express Scripts Simplifies Digital Health Technology Marketplace for Consumers and Payers

    ST. LOUIS, May 16, 2019 /PRNewswire/ -- To make it simpler for consumers and payers to navigate the hundreds of thousands of currently available personal health technologies and interventions, Express Scripts, a Cigna company, will introduce the industry's first, stand-alone digital health formulary. "We are in an exciting age when technology is giving people even greater control of their own health and well-being. "We see a need to put mechanisms in place to help carefully manage these innovations, and are proud to lead again by being the first health services organization to establish a formulary of this nature.

  • Investing.com

    Day Ahead: Top 3 Things to Watch

    Investing.com - Here’s a preview of the top 3 things that could rock markets tomorrow.

  • PR Newswire

    Accredo, a Full-Service Specialty Pharmacy, Expands Best-in-Class Services with New Pharmacy in Hawaii

    ST. LOUIS, April 16, 2019 /PRNewswire/ -- Express Scripts today announced that its specialty pharmacy, Accredo, will open a new location in Honolulu to provide high-touch pharmacy care to people living with chronic, complex health conditions, such as multiple sclerosis, cancer and hemophilia. AlohaCare, a Hawaii-based, non-profit health plan, has selected Accredo as its preferred specialty pharmacy to serve its members living on Oahu, Kauai, Molokai, Lanai, Maui and Hawaii Island. "With its mission to care for people who are underserved with specific health needs, AlohaCare is a leader in putting patients first," said Brian Seiz, President, Accredo.

  • Investing.com

    Cigna Shares Hit 52-Week Low on Trump Bid to Kill ACA

    Investing.com - The Trump Administration wants the entire Affordable Care Act (also known as Obamacare) declared unconstitutional and Cigna (NYSE:CI) shares fell back Tuesday as a result.

  • Moody's

    Diplomat Pharmacy, Inc. -- Moody's downgrades Diplomat Pharmacy's CFR to B2; negative outlook

    Moody's Investors Service ("Moody's") downgraded the ratings of Diplomat Pharmacy, Inc. ("Diplomat") including the Corporate Family Rating to B2 from B1, the Probability of Default Rating to B2-PD from B1-PD, the senior secured rating to B2 from B1, and the Speculative Grade Liquidity Rating to SGL-3 from SGL-2. The downgrade of the Corporate Family Rating to B2 from B1 reflects challenging conditions in Diplomat's two major operating segments -- specialty pharmacy and pharmacy benefit management (PBM) -- that will keep debt/EBITDA elevated above the 4.5x threshold that Moody's incorporated in the prior rating of B1.

  • Richard Pzena Exits Express Scripts, Reduces Dover
    GuruFocus.com

    Richard Pzena Exits Express Scripts, Reduces Dover

    Richard Pzena (Trades, Portfolio), t he founder and co-chief investment officer of Pzena Investment Management, sold shares of the following stocks during the fourth quarter. Warning! GuruFocus has detected 2 Warning Sign with QSR. The guru closed his Express Scripts Holding Co. (ESRX) stake.

  • Cigna Corp (CI) Q4 2018 Earnings Conference Call Transcript
    Motley Fool

    Cigna Corp (CI) Q4 2018 Earnings Conference Call Transcript

    CI earnings call for the period ending December 31, 2018.

  • Reuters

    Cigna CEO shrugs off concerns about proposed change to rebate rules

    The U.S. government's proposal to eliminate rebates that pharmacy benefit managers receive from drugmakers will not have a meaningful impact on growth, and does not affect the commercial market, Cigna Corp Chief Executive Officer David Cordani said on Friday. Investors are worried that Cigna, which closed its $52 billion acquisition of PBM Express Scripts in December, could be hurt by the Trump administration's proposal targeting after-market discounts that middlemen in the pharmaceutical supply chain have received for decades.

  • Anthem Stock Hits Buy Point Intraday On Strong Outlook, Earnings
    Investor's Business Daily

    Anthem Stock Hits Buy Point Intraday On Strong Outlook, Earnings

    Anthem stock vaulted higher, touching a buy point intraday, after the company issued a far-better-than-expected profit forecast this year.

  • Moody's

    Express Scripts Holding Company -- Moody's confirms Express Scripts at Baa2; stable outlook

    This concludes a rating review initiated on March 9, 2018 following the announcement that Cigna Corporation ("Cigna") reached a definitive agreement to acquire Express Scripts in a transaction valued at approximately $67 billion. Moody's changed the direction of the rating review from uncertain to downgrade on September 6, 2018.

  • Benzinga

    Analysts: Cigna Offers Earnings Growth Potential, But Faces Legal Risks Tied To Aborted Anthem Deal

    Cigna Holding Co (NYSE: CI) recently completed its acquisition of pharmacy benefit manager Express Scripts. Raymond James analyst John Ransom upgraded Cigna from Market Perform to Outperform with a $215 price target. Wells Fargo Securities analyst Peter Costa maintained a Market Perform rating for Cigna and lowered the price target from $221 to $200.

  • GuruFocus.com

    5 Health Care Stocks Gurus Are Buying

    Gilead on the list

  • 5 Great Healthcare Stocks to Buy for 2019
    Zacks

    5 Great Healthcare Stocks to Buy for 2019

    Rapid innovation, major advances and an ageing population have managed to sustain the popularity of healthcare stocks.

  • Moody's

    Connecticut General Life Insurance Company -- Moody's downgrades Cigna's long-term ratings (senior unsecured debt to Baa2); outlook stable

    Moody's Investors Service has downgraded Cigna Corporation's long-term ratings, including its senior unsecured debt rating to Baa2 from Baa1, upon the closing of its acquisition of Express Scripts Holding Company (ESI, Baa2, Review Down). Total senior unsecured debt of approximately $41 billion includes $20 billion issued by subsidiary Halfmoon Parent, Inc. (now known as Cigna Corporation), legacy Cigna Corporation (now known as Cigna Holding Company) debt of approximately $5.3 billion and legacy ESI debt of approximately $12.8 billion.